Veloxis Pharmaceuticals A/S Owners

Health Care & Life Sciences » Biotechnology | Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S | Ownership

Name

Shares Held

% Shares Out

Change In Shares

% of Assets

As of Date

Danske Bank A/S (Investment Management)

1,576,236

0.09%

08/31/2018

PlusAlpina Real Estate Advisors GmbH

939,419

0.06%

0.3%

08/31/2018

RAM Active Investments SA

28,265

-16,033

06/30/2017

Handelsbanken Fonder AB

-315,593

08/31/2018

View Profile

Address	Amerika Plads 37 Copenhagen CR 2100 Denmark
Employees	-
Website	http://www.veloxis.com
Updated	07/08/2019
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark.